Workpackage 5 of the Innovative Medicines Initiative Pharma-Cog (WP5 IMI Pharma-Cog)
The WP5 IMI Pharma-Cog project aimed to test the value and utility of computerized cognitive markers and biomarkers in the multi-modal characterization of prodromal Alzheimer’s Disease patients with amnesic mild cognitive impairment (aMCI). Between December 2011 and June 2013, around 150 aMCI patients were enrolled in 13 European memory clinics across the Netherlands, Spain, Germany, Italy, Greece, and France. Participants were followed up 6, 12, 18, 24, 3,0, and 36 months after baseline. This study is a part of the European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
Study design
Cohort
Number of participants at first data collection
147 (participants)
Age at first data collection
55 - 90 years (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Countries
Year of first data collection
2009
Primary Institutions
Innovative Medicines Initiative (IMI)
Links
kb.imi-neuronet.org/admin/projects/25
alz.org/research/for_researchers/partnerships/wwadni/european_adni
Profile paper DOI
Funders
European Union (EU)
Innovative Medicines Initiative (IMI)
Ministry of Economy, Finance and Industry (Ministère de l'Économie, des finances et de l'industrie, MEFI)
Ongoing?
No
Data types collected
- Computer, paper or task testing (e.g. cognitive testing, theory of mind doll task, attention computer tasks)
- Interview – unspecified
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- Self-report questionnaire – unspecified
- None
- Diffusion Tensor Imaging (DTI)
- Electroencephalography (EEG)
- Functional magnetic resonance imaging (fMRI)
- Magnetic Resonance Imaging (MRI)
- None
Engagement
Keywords
Consortia and dataset groups
